Please ensure Javascript is enabled for purposes of website accessibility

How Are COVID Vaccine Rollouts Going in Europe?

By Keith Speights - Jan 23, 2021 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bumps in the road for vaccinations aren't limited to the U.S.

Problems with COVID-19 vaccine rollouts in the U.S. have made headlines. But, as the old saying goes, the grass isn't always greener on the other side -- even if we're talking about the other side of the Atlantic. European countries are facing some challenges, too. In this Motley Fool Live video recorded on Jan. 13, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights discuss how the COVID-19 vaccine rollouts in Europe are going.

Corinne Cardina: Let's look abroad momentarily. How are things going with the vaccine regulatory and rollout in Europe?

Keith Speights: Well, in Europe, and when we say Europe, we have to differentiate there, Corinne, because you've got the European Union countries and then you've got the United Kingdom, which is no longer part of the European Union. There are two different factors at play there.

In the UK, they have authorized three vaccines thus far. They first started off with the Pfizer (PFE -1.94%)-BioNTech (BNTX -1.84%) vaccine, and then they gave authorization to Moderna's (MRNA -4.12%) vaccine and also AstraZeneca's (AZN -2.92%) vaccine that they developed along with the University of Oxford. The UK has three vaccines that are being rolled out. In the European Union, there are two vaccines, the Pfizer BioNTech vaccine, and Moderna's.

The population of Europe, including the EU countries and the UK combined, is more than 500 million people. They are encountering some of the same kind of issues that the US is having. Some countries have said they don't have enough healthcare workers to get all the vaccines out, they're running behind the schedule they had hoped.

They're even seeing some of the same issues we were just talking about with the federal government in the US and the states having some disconnects there. Well, the European Union is, you can think of that as a federal government in a way with each country like a state. There's been some miscommunication between the EU and the individual countries. They're running into some of those logistical issues. Their process is going slowly, just like in the US. But just as we're seeing in the US things picking up, I think we'll see it pick up in Europe as well.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$50.34 (-1.94%) $-1.00
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$63.73 (-2.92%) $-1.92
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$136.42 (-4.12%) $-5.86
BioNTech SE Stock Quote
BioNTech SE
BNTX
$156.86 (-1.84%) $-2.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.